ALFA Filings
Every announcement, straight from the exchange
Every Neuland Laboratories earnings call announcement on NSE and BSE, newest first, each with its own page.
Time
5 announcements
Q1FY27 was broadly in line with expectations, showing strong YoY revenue and profit growth. Management remains confident in achieving a 20% growth rate despite inherent quarterly volatility in the CMS business.
Neuland reported Q1FY27 total income of ₹650.1 Cr (116.3% YoY growth) with an EBITDA margin of 35.5%. Growth is driven by the CMS business and commercial molecules.
Neuland reported record performance for Q4FY26, driven by high-value CMS commercial projects and favorable exchange rates, achieving an exceptional 40.5% EBITDA margin.
Neuland Laboratories' March 2026 API Product List showcases a robust portfolio across diverse therapeutic segments including anticoagulants, antipsychotics, and peptides.
Neuland Laboratories delivered strong FY26 results with significant revenue and profit scaling, driven by the CMS business and commercial molecules. Strategy focuses on high-margin niches, peptides, and a new R&D center.